logo
  

Cliffs Natural Resources Plans To Exit Eastern Canadian Iron Ore Business

Cliffs Natural Resources Inc. (CLF) Wednesday said it is considering to exit its Eastern Canadian iron ore operations, that may lead to the closure of the Bloom Lake mine. The company expects closure costs to be in the range of $650 million to $700 million in the next five years.


Lourenco Goncalves, CEO said, with expansion no longer viable, the group has shifted its focus to executing an exit option for Eastern Canadian operations that minimizes the cash outflows and associated liabilities.


In addition, Cliffs said its unit, Cliffs Quebec Iron Mining Ltd., along with Bloom Lake General Partner Ltd. and The Bloom Lake Iron Ore Ltd. Partnership, recently lost an arbitration claim they filed against a former Bloom Lake customer relating to the termination of an iron ore sales agreement, back in August 2011. The arbitrators decided in favor of the former customer and awarded it damages in an amount of nearly $71 million as well as attorneys' fees and accrued interest from the date of termination of the offtake agreement in August.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT